Characteristics of surgical prosthetic heart valves and problems around labelling: a document from the European Association for Cardio-Thoracic Surgery (EACTS)-The Society of Thoracic Surgeons (STS)-American Association for Thoracic Surgery (AATS) Valve Labelling Task Force.

Aortic valve replacement Device approval International Organization for Standardization (ISO) International standard Labelling Mitral valve replacement Objective performance criteria (OPC) Prosthesis–patient mismatch (PPM) Prosthetic heart valve Regulation Sizing Surgical prosthetic heart valve (SHV) Valve performance

Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
01 06 2019
Historique:
received: 02 11 2018
revised: 08 01 2019
accepted: 17 01 2019
pubmed: 11 5 2019
medline: 2 10 2020
entrez: 11 5 2019
Statut: ppublish

Résumé

Intraoperative surgical prosthetic heart valve (SHV) choice is a key determinant of successful surgery and positive postoperative outcomes. Currently, many controversies exist around the sizing and labelling of SHVs rendering the comparison of different valves difficult. To explore solutions, an expert Valve Labelling Task Force was jointly initiated by the European Association for Cardio-Thoracic Surgery (EACTS), The Society of Thoracic Surgeons (STS) and the American Association for Thoracic Surgery (AATS). The EACTS-STS-AATS Valve Labelling Task Force, comprising cardiac surgeons, cardiologists, engineers, regulators and representatives from the International Organization for Standardization (ISO) and major valve manufacturers, held its first in-person meeting in February 2018 in Paris, France. This article was derived from the meeting's discussions. The Task Force identified the following areas for improvement and clarification: reporting of physical dimensions and characteristics of SHVs determining and labelling of SHV size, in vivo and in vitro testing and reporting of SHV haemodynamic performance and thrombogenicity. Furthermore, a thorough understanding of the regulatory background and the role of the applicable ISO standards, together with close cooperation between all stakeholders (including regulatory and standard-setting bodies), is necessary to improve the current situation. Cardiac surgeons should be provided with appropriate information to allow for optimal SHV choice. This first article from the EACTS-STS-AATS Valve Labelling Task Force summarizes the background of SHV sizing and labelling and identifies the most important elements where further standardization is necessary.

Identifiants

pubmed: 31075173
pii: 5487437
doi: 10.1093/ejcts/ezz034
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1025-1036

Informations de copyright

This article has been co-published with permission in the European Journal of Cardio-Thoracic Surgery, The Annals of Thoracic Surgery and The Journal of Thoracic and Cardiovascular Surgery. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. © 2019 European Association for Cardio-Thoracic Surgery, The Society of Thoracic Surgeons, and The American Association for Thoracic Surgery. Published by Oxford University Press and Elsevier Inc.

Auteurs

Andras P Durko (AP)

Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands.
Department of Cardiac Surgery, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary.

Stuart J Head (SJ)

Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands.

Philippe Pibarot (P)

Québec Heart and Lung Institute, Laval University, Quebec City, QC, Canada.

Pavan Atluri (P)

Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA.

Vinayak Bapat (V)

Department of Cardiovascular Surgery, New York-Presbyterian/Columbia University Medical Center, New York, NY, USA.

Duke E Cameron (DE)

Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.

Filip P A Casselman (FPA)

Department of Cardiovascular and Thoracic Surgery, OLV Clinic, Aalst, Belgium.

Edward P Chen (EP)

Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA.

Gry Dahle (G)

Department of Cardiothoracic and Thoracic surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway.

Tjark Ebels (T)

Department of Cardiothoracic Surgery, Amsterdam University Medical Center, Amsterdam, Netherlands.

John A Elefteriades (JA)

Department of Cardiothoracic Surgery, Yale University School of Medicine, New Haven, CT, USA.

Patrizio Lancellotti (P)

Department of Cardiology, GIGA Cardiovascular Sciences, University of Liège Hospital, Liège, Belgium.

Richard L Prager (RL)

Department of Cardiac Surgery, University of Michigan Hospital, Ann Arbor, MI, USA.

Raphael Rosenhek (R)

Department of Cardiology, Medical University of Vienna, Vienna, Austria.

Alan Speir (A)

Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA, USA.

Marco Stijnen (M)

LifeTec Group, Eindhoven, Netherlands.

Giordano Tasca (G)

Cardiovascular Department, Operative Unit of Cardiac Surgery, Hospital A. Manzoni, Lecco, Italy.

Ajit Yoganathan (A)

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology/Emory School of Medicine, Atlanta, GA, USA.

Thomas Walther (T)

Department of Thoracic and Cardiovascular Surgery, University Hospital Frankfurt, Johann Wolfgang Goethe University Frankfurt, Frankfurt, Germany.

Ruggero De Paulis (R)

Department of Cardiac Surgery, European Hospital, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH